Questionnaire

1. Long-term use of 3DR ARV therapy for the treatment of HIV-1 infection has been associated with toxicity, a high pill burden, and drug-drug interactions that are of particular concern in a population with a high burden of TB.

2. The drug profiles of newer ARV medications offer improvements in:

3. Historically, 2DR ARV therapy has been confined to use as:

4. Early studies of 2DR as ARV therapy for treatment-naïve PLWHIV and for switching therapy in virally suppressed patients with HIV-1 infection were unsuccessful because:

5. When used in a first-line regimen for the treatment of HIV-1 infection, and ARV with a very high barrier to resistance is:

6. Non-inferiority of fixed-dose DTG/3TC 2DR versus comparator 3DR for viral suppression and with no emergent resistance-associated mutations at Week 144 has been demonstrated when used as:

7. Among switch studies investigating DTG-based 2DR versus current 3DR in virologically suppressed participants with HIV-1, discontinuations of 2DR due to adverse events were reported for:

8. In treatment-naïve adults with HIV-1 infection participating in the GARDEL trial, 2DR LPV/r + 3TC ARV therapy demonstrated non-inferiority to 3DR LPV/r + 2NRTIs in patients with a VL:

9. Studies demonstrating non-inferiority of switching to 2DR Dar/r + DTG or 3TC from 3DR Dar/r-based ARV therapy in virologically suppressed adults with HIV-1 infection reported a six-fold greater incidence of treatment discontinuation due to adverse events in the 3DR arm.

10. 2DR ARV therapies with proven efficacy for initial treatment or switching therapies in virally suppressed adults infected with HIV-1 that are currently available in South Africa are: